Intestinal Microbiota and Treatment of GD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-12-23

Study Completion Date

2019-12-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in GD patients and healthy controls and analyse the relationship between intestinal microbiota and GD drug therapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Gut Microbiota is Associated With Autoimmune Thyroid Disease

NCT03390582

Gut Microbiota

UNKNOWN

The Oral Microbiota is Associated With Autoimmune Thyroiditis

NCT03447093

Microbiota

UNKNOWN

Change of Gut Microbiome in the Treatment of Graves' Disease

NCT04383795

Graves' Disease

COMPLETED

Observation in the Treatment of Graves' Disease

NCT05043233

Patient Acceptance of Health Care

UNKNOWN

A Clinical Follow-up Study on Drug Therapy for Graves' Disease Patients in China

NCT07040306

Graves´ Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in GD patients and healthy controls before and found that gut microbiota changed between GD patients and healthy controls.But there are few articles on the relationship between intestinal microbiota and drug treatment of GD, so Investigators explored the relationship between intestinal microflora and methimazole treatment for GD.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Microbiota

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control group

30 healthy volunteers were included in the healthy control group

No interventions assigned to this group

Recrudescence group

30 GD patients who received recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill

Methimazole Pill

Intervention Type DRUG

Patients who developed GD received methimazole treatment

Propylthiouracil Pill

Intervention Type DRUG

Patients who developed GD received propylthiouracil treatment

No recrudescence group

30 GD patients who did not receive recurrence within 2 years after treatment with Methimazole Pill or propylthiouracil pill

Methimazole Pill

Intervention Type DRUG

Patients who developed GD received methimazole treatment

Propylthiouracil Pill

Intervention Type DRUG

Patients who developed GD received propylthiouracil treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Methimazole Pill

Patients who developed GD received methimazole treatment

Intervention Type DRUG

Propylthiouracil Pill

Patients who developed GD received propylthiouracil treatment

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 to 65 years
* GD was clinical diagnosed and accept the standard treatment of methimazole or propylthiouracil and thyroid function returned to normal

Exclusion Criteria

* Pregnancy
* Lactation
* Cigarette smoking
* Alcohol addiction
* Hypertension
* Diabetes mellitus
* Lipid dysregulation
* BMI \> 27
* Recent (\< 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or Chinese herbal medicine
* History of disease with an autoimmune component, such as MS, rheumatoid arthritis, IBS, or IBD
* History of malignancy or any gastrointestinal tract surgery

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes